EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Size-Controlled Mesoporous Silica Nanoparticles via Template Nanoarchitectonics from a Deferoxamine Derivative for Enhanced Blood–Brain Barrier Permeability and Neuroprotective Chelation Therapy

Mónica Onrubia-Márquez iD, Francisco Navas, Esther M Sánchez-Carnerero iD, Antonio Martín iD, Anselma Liturri iD, Morena Miciaccia iD, Raúl Sanz iD, Antonio Scilimati iD, Rafael A García-Muñoz iD, Maria Grazia Perrone iD, Victoria Morales iD

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.5c18528 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2025. Verfasst von Mónica Onrubia-Márquez und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Environmental Technology, ESCET, Universidad Rey Juan Carlos, 28933 Móstoles, Madrid, Spain. Hauptthemen laut MEDLINE: Blood-Brain Barrier, Silicon Dioxide, Deferoxamine, Nanoparticles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Estatal de Investigación, Ministero dell'Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative diseases (NDs) are progressive and fatal disorders that primarily affect the elderly and remain incurable. Characterized by irreversible neuronal loss, they leave patients increasingly dependent on caregivers. Despite diverse clinical presentations, NDs share common pathological features, such as protein aggregation, metal accumulation, oxidative stress, and chronic neuroinflammation. Despite numerous efforts, most therapeutic candidates fail due to poor efficacy, toxicity concerns, or limited blood-brain barrier (BBB) permeability, thereby highlighting the need for enhanced formulations. Nanomedicine offers a promising strategy to improve the therapeutic performance of existing compounds. This study presents a nanoformulation of the metal chelator deferoxamine (DFO) based on the drug-structure-directing agent (DSDA) concept, in which a hydrophobic chain is covalently linked to the DFO molecule to impart amphiphilic properties and acts as a template for the synthesis of a mesoporous silica nanoparticle (MSN). This approach allows for the one-pot fabrication of DFO-loaded MSNs (DFO@MSNs) with controlled sizes of below 20 nm without the need for surfactant removal. Compared to MCM-41-based systems, DFO@MSNs exhibited a higher drug loading capacity (10 mg of DFO/100 mg of MSNs) and a significantly more sustained release profile, minimizing premature leakage, with less than 20% of the cargo released over 24 h. Safety of DFO@MSN was assessed using BV-2 microglial and human neuroblastoma SH-SY5Y cell lines, and in vitro assays confirmed its enhanced iron-chelating capacity and effective inhibition of aluminum-induced amyloid aggregation. Furthermore, permeability studies using a Caco-2 in vitro BBB model revealed that a smaller particle size greatly enhances transport across the barrier. These results support DFO@MSNs as a promising multifunctional nanoplatform for targeted chelation therapy and neuroprotection in ND treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood-Brain BarrierSilicon DioxideDeferoxamineNanoparticlesNeuroprotective AgentsHumansPorosityChelation TherapyPermeabilityParticle SizeAnimalsCaco-2 Cells

Stichwörter der Autor:innen

Deferoxamineamyloid misfoldingblood−brain barrierchelation therapymesoporous silica nanoparticlesneuroprotection

Substanzen

Silicon DioxideDeferoxamineNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Chemical and Environmental Technology, ESCET, Universidad Rey Juan Carlos, 28933 Móstoles, Madrid, Spain.
  • Research Laboratory for Woman and Child Health, Department of Pharmacy-Pharmaceutical Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.
  • Instituto de Investigación de Tecnologías para la Sostenibilidad, Universidad Rey Juan Carlos (URJC), 28933 Móstoles, Madrid, Spain.

ORCID-Profile: Mónica Onrubia-Márquez, Esther M Sánchez-Carnerero, Antonio Martín, Anselma Liturri, Morena Miciaccia, Raúl Sanz, Antonio Scilimati, Rafael A García-Muñoz, Maria Grazia Perrone, Victoria Morales

Förderung

  • Agencia Estatal de Investigación
  • Ministero dell'Università e della Ricerca

Zitieren

APA

Onrubia-Márquez, M., Navas, F., Sánchez-Carnerero, E. M., Martín, A., Liturri, A., Miciaccia, M., Sanz, R., Scilimati, A., García-Muñoz, R. A., Perrone, M. G., & Morales, V. (2025). Size-Controlled Mesoporous Silica Nanoparticles via Template Nanoarchitectonics from a Deferoxamine Derivative for Enhanced Blood–Brain Barrier Permeability and Neuroprotective Chelation Therapy. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c18528

Vancouver

Onrubia-Márquez M, Navas F, Sánchez-Carnerero EM, Martín A, Liturri A, Miciaccia M, et al. Size-Controlled Mesoporous Silica Nanoparticles via Template Nanoarchitectonics from a Deferoxamine Derivative for Enhanced Blood–Brain Barrier Permeability and Neuroprotective Chelation Therapy. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c18528

BibTeX
@article{OnrubiaMrquez2025,
  author = {Onrubia-Márquez, Mónica and Navas, Francisco and Sánchez-Carnerero, Esther M and Martín, Antonio and Liturri, Anselma and Miciaccia, Morena and Sanz, Raúl and Scilimati, Antonio and García-Muñoz, Rafael A and Perrone, Maria Grazia and Morales, Victoria},
  title = {Size-Controlled Mesoporous Silica Nanoparticles via Template Nanoarchitectonics from a Deferoxamine Derivative for Enhanced Blood–Brain Barrier Permeability and Neuroprotective Chelation Therapy},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.5c18528}
}
Kostenlos starten →